Jiangsu Nhwa Pharmaceutical Co., LTD (SHE: 002262)

Jiangsu Nhwa Pharmaceutical Co., LTD Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	5,465	4,976	4,255	3,919	3,344	4,133
Other Revenue	65.63	65.63	43.49	16.53	16.99	16.62
Revenue	5,531	5,042	4,299	3,936	3,361	4,149
Revenue Growth (YoY)	14.41%	17.28%	9.22%	17.09%	-18.99%	7.55%
Cost of Revenue	1,508	1,403	1,037	932.68	843.14	1,561
Gross Profit	4,023	3,638	3,262	3,003	2,518	2,588
Selling, General & Admin	2,122	1,944	1,847	1,743	1,443	1,650
Research & Development	600.27	549.32	454.25	351.73	245.86	188.97
Other Operating Expenses	70.13	60.2	57.46	54.04	45.61	47.68
Operating Expenses	2,810	2,569	2,360	2,156	1,737	1,900
Operating Income	1,213	1,070	901.63	847.28	781.53	688.01
Interest Expense	-4.19	-4.16	-4.95	-5.06	-1.59	-15.99
Interest & Investment Income	83.26	74.85	61.8	53.92	48.32	74.35
Currency Exchange Gain (Loss)	0.41	0.41	0.91	-1.14	-0.38	-0.11
Other Non Operating Income (Expenses)	3.86	-0.74	-3.19	-1.62	1.43	-7.57
EBT Excluding Unusual Items	1,297	1,140	956.2	893.38	829.31	738.7
Impairment of Goodwill	-	-	-	-	-0.82	-
Gain (Loss) on Sale of Assets	1.28	0.15	0.37	-0.24	-0.15	-0.17
Asset Writedown	7.15	0.22	-0.28	-0.74	-0.21	-0.1
Other Unusual Items	15.23	28.32	33.62	23.38	22.35	28.67
Pretax Income	1,320	1,169	989.91	915.78	850.48	767.1
Income Tax Expense	152.9	134.4	109.82	117.75	123.37	110.02
Earnings From Continuing Operations	1,167	1,034	880.09	798.02	727.1	657.07
Minority Interest in Earnings	4.01	2.67	20.62	-0.24	1.72	6.23
Net Income	1,171	1,037	900.71	797.78	728.82	663.31
Net Income to Common	1,171	1,037	900.71	797.78	728.82	663.31
Net Income Growth	12.15%	15.12%	12.90%	9.46%	9.88%	26.39%
Shares Outstanding (Basic)	1,009	1,007	1,012	1,010	1,012	1,005
Shares Outstanding (Diluted)	1,009	1,007	1,012	1,010	1,012	1,005
Shares Change (YoY)	-0.54%	-0.53%	0.22%	-0.24%	0.72%	-0.42%
EPS (Basic)	1.16	1.03	0.89	0.79	0.72	0.66
EPS (Diluted)	1.16	1.03	0.89	0.79	0.72	0.66
EPS Growth	12.76%	15.73%	12.66%	9.72%	9.09%	26.92%
Free Cash Flow	672.72	634.31	533.27	495.01	979.74	145.67
Free Cash Flow Per Share	0.67	0.63	0.53	0.49	0.97	0.14
Dividend Per Share	0.320	0.320	0.200	0.200	0.100	0.100
Dividend Growth	60.00%	60.00%	0%	100.00%	0%	66.67%
Gross Margin	72.73%	72.17%	75.88%	76.30%	74.92%	62.38%
Operating Margin	21.94%	21.22%	20.98%	21.53%	23.25%	16.58%
Profit Margin	21.18%	20.57%	20.95%	20.27%	21.68%	15.99%
Free Cash Flow Margin	12.16%	12.58%	12.41%	12.58%	29.15%	3.51%
EBITDA	1,357	1,204	1,025	959.57	878.36	776.16
EBITDA Margin	24.53%	23.89%	23.84%	24.38%	26.13%	18.71%
D&A For EBITDA	143.52	134.78	123.12	112.28	96.83	88.15
EBIT	1,213	1,070	901.63	847.28	781.53	688.01
EBIT Margin	21.94%	21.22%	20.98%	21.53%	23.25%	16.58%
Effective Tax Rate	11.58%	11.50%	11.09%	12.86%	14.51%	14.34%
Revenue as Reported	5,531	5,042	4,299	3,936	3,361	4,149

Source: S&P Capital IQ. Standard template. Financial Sources.